High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma.
Anticancer Res
; 40(10): 5631-5639, 2020 Oct.
Article
in En
| MEDLINE
| ID: mdl-32988887
ABSTRACT
BACKGROUND/AIM:
DNA damage response (DDR), wherein p21 is a cell fate determinant, is a potential cancer therapeutic target. Molecular expression during DDR was explored in ovarian clear-cell carcinoma (CCC). MATERIALS ANDMETHODS:
CHK1, CHK2, TP53 and p21 expression in DDR was examined using immunostaining in surgical sections of CCC (n=22). Molecular alterations in two types of CCC cell lines, JHOC-5 and JHOC-9, were investigated using western blot analysis.RESULTS:
Expression of DDR-associated molecules was noted in most patients. While high p21 expression was found in half of the patients, the remaining patients exhibited low p21 expression. Treatment with UC2288, a p21 inhibitor, attenuated proliferation of both cell lines, more prominently in JHOC-9, resulting in reduced viability and subsequent apoptosis.CONCLUSION:
p21 Inhibitor induced cell death in cells with high p21 expression, suggesting that p21 suppression can be a therapeutic strategy to treat patients with CCC.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Tumor Suppressor Protein p53
/
Cyclin-Dependent Kinase Inhibitor p21
/
Checkpoint Kinase 2
/
Checkpoint Kinase 1
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Anticancer Res
Year:
2020
Document type:
Article
Affiliation country:
Japón